Sonic Incytes
- Company typePrivate
- Founded2017
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Sonic Incytes firmographics
Firmographics- Name
- Sonic Incytes
- Legal name
- Sonic Incytes Medical Corp.
- Website
- https://sonicincytes.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Sonic Incytes industry classification
Industry- Product category
- Medical Imaging Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Ultrasound & Echography Systems (HLAHABAD)
- akta.pro secondary industries
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Quality, Peer Review & Compliance Tools (MQSA/ACR/QA) (HLACALAL)
Keywords
Where Sonic Incytes is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Sonic Incytes business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Medical Device Sales: Sale of Velacur and Velacur ONE ultrasound elastography devices to healthcare providers including gastroenterology practices, hepatology clinics, and point-of-care settings. Device includes hardware (probe, activation pad) and pre-installed AI-guided software.
- Reimbursement for Procedures: Healthcare providers bill using CPT codes 76981 (ultrasound elastography with B-mode imaging) and potentially 91200. Velacur with B-mode imaging enables 3-4X higher reimbursement compared to non-imaging elastography.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Medical Device - Quote-based pricing |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels8 records
Sonic Incytes product offering
Product offeringCore offering
Sonic Incytes develops and sells the Velacur line of AI-guided ultrasound elastography devices for non-invasive point-of-care assessment of chronic liver diseases, including MASLD and MASH. The flagship Velacur ONE combines B-mode imaging, liver stiffness (elasticity), attenuation (ACE), and fat fraction (VDFF) measurements using 3D S-WAVE technology, enabling rapid liver assessment without biopsy or MRI. The company sells these medical devices directly to gastroenterology, hepatology, primary care, and clinical research customers.
Product overview
Sonic Incytes offers the Velacur™ product line, an AI-guided ultrasound elastography system for non-invasive liver disease assessment. The portfolio consists of Velacur ONE™ (current flagship point-of-care device) and Velacur™ Classic (original model), both utilizing 3D S-WAVE technology with AI guidance for liver stiffness and attenuation measurements. The VDFF (Velacur Determined Fat Fraction) module is a software feature integrated into both devices that estimates liver fat content by combining attenuation and backscatter measurements. The products are designed for point-of-care use by any trained medical professional, enabling assessment of MASLD and MASH without requiring sonography expertise.
Differentiator
Problem solved
Functional benefit
Brands
- Velacur ONE: AI-guided point-of-care ultrasound elastography device for assessments of chronic liver diseases including MASLD and MASH.
- Velacur Classic
Products and services
- Velacur ONE™ AI-guided point-of-care ultrasound elastography device for assessment of chronic liver diseases including MASLD and MASH. Measures liver stiffness (elasticity), attenuation (ACE), and Velacur Determined Fat Fraction (VDFF) using 3D S-WAVE technology with B-mode imaging capability. Features AI-based organ overlay for liver localization and enables 3-4x higher reimbursement than non-imaging elastography.
- Velacur™ Classic Original AI-guided 3D S-WAVE ultrasound elastography device that measures liver stiffness, attenuation, and VDFF as key indicators of fatty liver disease. Designed for point-of-care use with AI guidance enabling confident measurement by operators without sonography experience.
- VDFF (Velacur Determined Fat Fraction) Proprietary measurement tool integrated into the Velacur device software that combines quantitative measures of ultrasound attenuation and backscatter to estimate MRI-PDFF. Delivers similar clinical utility to MRI-PDFF at the point of care for hepatic steatosis assessment, with FDA 510(k) clearance as a standalone measurement capability.
Quantifiable outcome
- 91% increase in liver elastography volume (Capital Digestive Care case study)
- +7 more outcomes
Companies that use Sonic Incytes
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Sonic Incytes technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature6 records
Sonic Incytes partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- MASHNET MASLD Diagnostic CoalitioncoreSonic Incytes is a founding member of the MASLD Diagnostic Coalition formed by MASHNET to improve access and awareness of non-invasive diagnostics for MASLD. Coalition includes Echosens, E-Scopics, Labcorp, Perspectum, Siemens Healthineers, and is supported by Novo Nordisk. Aims to advance early detection, public education, and collaborative efforts to address underdiagnosis and rising prevalence of MASLD and MASH.
Scale indicators5 records
Recent moves6 records
Expansion highlights7 records
Sonic Incytes competitors and assessment
Company assessmentDirect peers
- Echosens: Echosens is the dominant point-of-care liver elastography vendor with FibroScan, the established non-invasive standard for liver fibrosis and steatosis assessment. Most direct competitor to Velacur in GI/hepatology practices.
Broad incumbents
- GE HealthCare: GE HealthCare manufactures LOGIQ ultrasound systems used broadly in clinical imaging including elastography applications. A broad incumbent with overlapping liver imaging capabilities but not specialized in point-of-care liver assessment like Sonic Incytes.
- Siemens Healthineers: Siemens Healthineers produces ACUSON ultrasound systems with shear wave elastography capabilities used in radiology and hepatology. A broad incumbent in clinical ultrasound, also a MASHNET coalition member alongside Sonic Incytes.
- Philips Healthcare: Philips offers EPIQ and Affiniti ultrasound platforms with elastography functionality for liver and other applications. A broad incumbent competing in the same provider purchasing decisions as Velacur at IDNs and academic centers.
- Canon Medical Systems: Canon Medical manufactures Aplio ultrasound systems with shear wave elastography for liver applications. A broad incumbent in clinical ultrasound imaging with overlapping elastography capabilities.
Emerging players
- E-Scopics: E-Scopics develops portable ultrasound solutions for point-of-care use cases including liver assessment. A fellow MASHNET coalition member with an emerging device-focused approach similar to Sonic Incytes' strategy.
- Perspectum: Perspectum offers LiverMultiScan, an MRI-based quantitative liver assessment tool for MASLD/MASH. An emerging non-invasive liver diagnostic competitor using a different modality (MRI vs ultrasound). Also a MASHNET coalition member.
Others
- Mindray: Mindray is a global medical device manufacturer offering a broad ultrasound portfolio including systems with elastography functionality. A broader competitor in clinical ultrasound equipment not specialized in liver assessment.
- Samsung Medison: Samsung Medison manufactures diagnostic ultrasound systems including elastography-capable platforms. A broader ultrasound equipment competitor with overlapping but not specialized liver assessment focus.
- Labcorp: Labcorp provides blood-based diagnostics including liver disease biomarker tests. A MASHNET coalition partner and adjacent competitor through laboratory diagnostics for MASLD/MASH assessment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Sonic Incytes social profiles
Digital presenceSonic Incytes compliance and trust
Trust signalCompliance1 record
Sonic Incytes financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sonic Incytes leadership team
Management profileNumber of profiles
Profiles14 records
Sonic Incytes funding detail
Funding detailFunding overview
Funding rounds6 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sonic Incytes M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sonic Incytes
What does Sonic Incytes do?
Sonic Incytes develops and sells the Velacur line of AI-guided ultrasound elastography devices for non-invasive point-of-care assessment of chronic liver diseases, including MASLD and MASH. The flagship Velacur ONE combines B-mode imaging, liver stiffness (elasticity), attenuation (ACE), and fat fraction (VDFF) measurements using 3D S-WAVE technology, enabling rapid liver assessment without biopsy or MRI. The company sells these medical devices directly to gastroenterology, hepatology, primary care, and clinical research customers.
Is Sonic Incytes a public or private company?
Sonic Incytes is a private company. It is classified as venture growth investor backed and is currently operating.
When was Sonic Incytes founded?
Sonic Incytes was founded in 2017. It employs 11 to 50 people.
Where is Sonic Incytes based?
Sonic Incytes is headquartered in Vancouver, Canada, in the North America region.
How does Sonic Incytes make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are reimbursement for Procedures.
Who are Sonic Incytes's main competitors?
Echosens is listed as a direct peer. Broad incumbents are GE HealthCare, Siemens Healthineers, Philips Healthcare and Canon Medical Systems. Emerging players are E-Scopics and Perspectum. Others are Mindray, Samsung Medison and Labcorp.
Does Sonic Incytes have an API?
No public API is recorded for Sonic Incytes.
What industry is Sonic Incytes in?
Sonic Incytes's product category is Medical Imaging Devices. Its primary akta.pro industry code is HLAHABAD, Ultrasound & Echography Systems, with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its NAICS code is 334510 and its SIC code is 3841.